Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis

Perini, P.; Ranzato, F.; Calabrese, M.; Battistin, L.; Gallo, Paolo
August 2006
Journal of Neurology, Neurosurgery & Psychiatry;Aug2006, Vol. 77 Issue 8, p953
Academic Journal
The intrathecal synthesis of IgM, determined at clinical onset in patients with multiple sclerosis, was found to correlate with the degree of disability (as evaluated by means of the Expanded Disability Status Scale) reached 15 years later (p<0.001). Moreover, a significant inverse correlation was observed between the value of the IgM index and time to the first relapse (p<0.001) and the initiation of the progressive phase of the disease (p=0.01). The prognostic value of IgM in the CSF is confirmed in previous reports as well as by our study. If these findings are confirmed in patients with multiple sclerosis in a larger series, a helpful biological marker for selecting patients for immunomodulatory treatments will be available to neurologists.


Related Articles

  • Short Papers.  // Neurological Sciences;Mar2004 Supplement 1, Vol. 25, ps31 

    Presents several short papers related to neurology. "Diagnosis of Primary Progressive Multiple Sclerosis," by X. Montalban; "The Diagnosis of Relapsing-Emitting Form," by G. Comi; "Immunological Markers," by T. Berger; "Monitoring of Functional Deficits: Multiple Sclerosis," by L. Leocani and...

  • Clinical and demographic factors affecting disease severity in patients with multiple sclerosis. Baghizadeh, Somayeh; Sahraian, Mohammad Ali; Beladimoghadam, Nahid // Iranian Journal of Neurology;2013, Vol. 12 Issue 1, p1 

    Background: The clinical course of multiple sclerosis (MS) evolves over many years. Its prognosis is highly variable among affected individuals, i.e. while some suffer from early severe disabilities, others remain ambulatory and functional for many years. We used Multiple Sclerosis Severity...

  • No evidence for an association of osteopontin plasma levels with disease activity in multiple sclerosis. Runia, Tessel F; van Meurs, Marjan; Nasserinejad, Kazem; Hintzen, Rogier Q // Multiple Sclerosis Journal;Oct2014, Vol. 20 Issue 12, p1670 

    A letter to the editor is presented in response to the article "Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development" by P. Kivisakk, B. C. Healy, K. Francois and colleagues in the 2013 issue.

  • ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Cotte, S.; Von Ahsen, N.; Kruse, N.; Huber, B.; Winkelmann, A.; Zettl, U. K.; Starck, M.; König, N.; Tellez, N.; Dörr, J.; Paul, F.; Zipp, F.; Lühder, F.; Pannek, H.; Montalban, X.; Gold, R.; Chan, A.; Koepsell, H. // Brain: A Journal of Neurology;Sep2009, Vol. 132 Issue 9, p2517 

    Escalation therapy with mitoxantrone (MX) in highly active multiple sclerosis is limited by partially dose-dependent side-effects. Predictors of therapeutic response may result in individualized risk stratification and MX dosing. ATP-binding cassette-transporters ABCB1 and ABCG2 represent...

  • Prognostische und prädiktiv relevante Faktoren bei der Multiplen Sklerose. Tackenberg, B.; Schneider-Hohendorf, T.; Müller, A.; Schodrowski, J.; Wiendl, H. // Der Nervenarzt;Oct2014, Vol. 85 Issue 10, p1255 

    The immunotherapy of multiple sclerosis (MS) is currently one of the most dynamic fields in clinical neurology. The comprehensive number of well-established and new innovative treatment options are a challenge for an intensive preoccupation with the differential indications and an...

  • Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation. Beltrán, Eduardo; Obermeier, Birgit; Moser, Markus; Coret, Francisco; Simó-Castelló, María; Boscá, Isabel; Pérez-Miralles, Francisco; Villar, Luisa M.; Senel, Makbule; Tumani, Hayrettin; Hohlfeld, Reinhard; Casanova, Bonaventura; Dornmair, Klaus // Brain: A Journal of Neurology;Oct2014, Vol. 137 Issue 10, p2703 

    Oligoclonal bands in the cerebrospinal fluid are the most important immunological marker of multiple sclerosis. Whereas oligoclonal IgG bands have been intensively studied, little is known about intrathecal IgM antibodies. Using state-of-the-art technologies, including deep sequencing and...

  • Word on the Street.  // BioWorld Insight;8/20/2012, Vol. 20 Issue 34, p6 

    The article discusses the use of microRNAs as biomarkers for multiple sclerosis.

  • Identifying responders and nonresponders to interferon therapy in multiple sclerosis. Prosperini, Luca; Capobianco, Marco; Giannì, Costanza // Degenerative Neurological & Neuromuscular Disease;2014, Vol. 4, p75 

    Interferon beta is a well established disease-modifying agent used for relapsing-remitting multiple sclerosis. Despite treatment, a relevant proportion of patients continue to experience clinical (ie, relapses, worsening of disability) and magnetic resonance imaging (MRI) activity. Early...

  • POI08 Serum C4a levels in multiple sclerosis correlate with disease activity. G Ingram // Journal of Neurology, Neurosurgery & Psychiatry;Nov2010, Vol. 81 Issue 11, pe54 

    Complement is known to play a key role in MS and recent work utilising proteomic analysis identified raised serum levels of C4a in patients compared to controls which decreased following relapse. In order to replicate and validate this finding which has significant implications for the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics